Utilizing conventional MRI to predict molecular subtypes of breast cancer.

Q2 Medicine

Clinica Terapeutica Pub Date : 2025-09-01 DOI:10.7417/CT.2025.5268

Tran Thi Hue, Nguyen Thu Huong, Nguyen Duy Hung

{"title":"Utilizing conventional MRI to predict molecular subtypes of breast cancer.","authors":"Tran Thi Hue, Nguyen Thu Huong, Nguyen Duy Hung","doi":"10.7417/CT.2025.5268","DOIUrl":null,"url":null,"abstract":"Objective: The study aimed to investigate the correlation between conventional magnetic resonance imaging (cMRI) features and molecular subtypes of breast cancer (BC) to enhance non-invasive diagnostic accuracy.Materials and methods: A total of 153 patients with breast cancer were included in this retrospective analysis. Tumors were classified into molecular subtypes based on immunohistochemical (IHC) criteria. cMRI findings were analyzed according to the 2013 BI-RADS system. Univariate and multivariate statistical analyses were performed to identify the MRI features most predictive of each molecular subtypes.Results: This study analyzed cMRI features in 153 breast cancer patients, classified into five molecular subtypes: Luminal A (LA, 39.9%), Luminal B HER2-negative (LB (-), 22.9%), Luminal B HER2-positive (LB (+), 9.2%), HER2-enriched (HER-2, 17.6%), and triple-negative (TNBC, 10.4%). LA was associated with absence of lymph node involvement (OR = 2.97, p = 0.039), spiculated margins (OR = 2.24, p = 0.009), no surrounding edema (OR = 4.65, p = 0.008), and low T2 signal intensity (OR = 6.24, p = 0.001). HER-2 tended to present as non-mass enhancement lesions (OR = 6.7, p = 0.001) and washout kinetic patterns (OR = 2.37, p = 0.001). Circumscribed margins (OR = 3.38, p = 0.001) and rim enhancement (OR = 2.97, p = 0.008) were independent predictors of TNBC . There were no associations between cMRI features and LB (-), LB (+).Conclusion: This study suggests that cMRI features can help differentiate breast cancer subtypes, such as LA, HER-2, and TNBC, serving as useful supplements to imunohistochemistry and clinical data.","PeriodicalId":50686,"journal":{"name":"Clinica Terapeutica","volume":"176 5","pages":"573-581"},"PeriodicalIF":0.0000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinica Terapeutica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.7417/CT.2025.5268","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 0

Abstract

Objective: The study aimed to investigate the correlation between conventional magnetic resonance imaging (cMRI) features and molecular subtypes of breast cancer (BC) to enhance non-invasive diagnostic accuracy.

Materials and methods: A total of 153 patients with breast cancer were included in this retrospective analysis. Tumors were classified into molecular subtypes based on immunohistochemical (IHC) criteria. cMRI findings were analyzed according to the 2013 BI-RADS system. Univariate and multivariate statistical analyses were performed to identify the MRI features most predictive of each molecular subtypes.

Results: This study analyzed cMRI features in 153 breast cancer patients, classified into five molecular subtypes: Luminal A (LA, 39.9%), Luminal B HER2-negative (LB (-), 22.9%), Luminal B HER2-positive (LB (+), 9.2%), HER2-enriched (HER-2, 17.6%), and triple-negative (TNBC, 10.4%). LA was associated with absence of lymph node involvement (OR = 2.97, p = 0.039), spiculated margins (OR = 2.24, p = 0.009), no surrounding edema (OR = 4.65, p = 0.008), and low T2 signal intensity (OR = 6.24, p = 0.001). HER-2 tended to present as non-mass enhancement lesions (OR = 6.7, p = 0.001) and washout kinetic patterns (OR = 2.37, p = 0.001). Circumscribed margins (OR = 3.38, p = 0.001) and rim enhancement (OR = 2.97, p = 0.008) were independent predictors of TNBC . There were no associations between cMRI features and LB (-), LB (+).

Conclusion: This study suggests that cMRI features can help differentiate breast cancer subtypes, such as LA, HER-2, and TNBC, serving as useful supplements to imunohistochemistry and clinical data.

查看原文本刊更多论文

利用常规MRI预测乳腺癌的分子亚型。

目的：探讨常规磁共振成像（cMRI）特征与乳腺癌分子亚型的相关性，以提高乳腺癌的无创诊断准确性。材料与方法：153例乳腺癌患者纳入回顾性分析。根据免疫组织化学（IHC）标准将肿瘤分为分子亚型。根据2013 BI-RADS系统分析cMRI结果。进行单变量和多变量统计分析，以确定每种分子亚型最具预测性的MRI特征。结果：本研究分析了153例乳腺癌患者的cMRI特征，将其分为5种分子亚型：Luminal A （LA, 39.9%）、Luminal B her2阴性（LB(-), 22.9%）、Luminal B her2阳性（LB(+), 9.2%）、her2富集（HER-2, 17.6%）和三阴性（TNBC, 10.4%）。LA与淋巴结未受累（OR = 2.97, p = 0.039）、边缘多刺（OR = 2.24, p = 0.009）、周围无水肿（OR = 4.65, p = 0.008）和低T2信号强度（OR = 6.24, p = 0.001）相关。HER-2倾向于表现为非肿块增强病变（OR = 6.7, p = 0.001）和洗脱动力学模式（OR = 2.37, p = 0.001）。边缘受限（OR = 3.38, p = 0.001）和边缘增强（OR = 2.97, p = 0.008）是TNBC的独立预测因子。cMRI特征与LB（-）、LB（+）无相关性。结论：本研究提示cMRI特征可以帮助区分乳腺癌亚型，如LA、HER-2和TNBC，作为免疫组织化学和临床数据的有用补充。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinica Terapeutica PHARMACOLOGY & PHARMACY-

CiteScore

2.50

自引率

0.00%

发文量

124

审稿时长

6-12 weeks

期刊介绍： La Clinica Terapeutica è una rivista di Clinica e Terapia in Medicina e Chirurgia, fondata nel 1951 dal Prof. Mariano Messini (1901-1980), Direttore dell''Istituto di Idrologia Medica dell''Università di Roma “La Sapienza”. La rivista è pubblicata come “periodico bimestrale” dalla Società Editrice Universo, casa editrice fondata nel 1945 dal Comm. Luigi Pellino. La Clinica Terapeutica è indicizzata su MEDLINE, INDEX MEDICUS, EMBASE/Excerpta Medica.